GTBP - GT Biopharma, Inc.
Previous close
3.14
0.900 28.662%
Share volume: 0
Last Updated: Tue 24 Dec 2024 06:14:50 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
35.29%
PREVIOUS CLOSE
CHG
CHG%
$2.24
0.90
40.18%
Fundamental analysis
4%
Profitability
0%
Dept financing
0%
Liquidity
0%
Performance
10%
Performance
5 Days
83.38%
1 Month
8.11%
3 Months
58.02%
6 Months
8.47%
1 Year
1,129.82%
2 Year
193.58%
Key data
Stock price
$3.14
DAY RANGE
$2.24 - $3.00
52 WEEK RANGE
$0.27 - $10.50
52 WEEK CHANGE
-$57.69
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
Company detail
CEO: Michael Breen
Region: US
Website: gtbiopharma.com
Employees: 8
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: gtbiopharma.com
Employees: 8
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
GT Biopharma, Inc. focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate, is in Phase I/II clinical trial for the treatment of myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia or advanced systemic mastocytosis, and CD33+ malignancies. The company was formerly known as OXIS International, Inc
Recent news